 Edward Dempsey
Concepts (332)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neprilysin | 6 | 2017 | 45 | 2.260 |
Why?
| | Muscle, Smooth, Vascular | 22 | 2017 | 450 | 2.160 |
Why?
| | Protein Kinase C | 15 | 2007 | 252 | 1.720 |
Why?
| | Pulmonary Artery | 26 | 2020 | 1117 | 1.670 |
Why?
| | Hypoxia | 18 | 2021 | 1165 | 1.150 |
Why?
| | rho GTP-Binding Proteins | 2 | 2020 | 60 | 1.140 |
Why?
| | Pulmonary Circulation | 7 | 2009 | 438 | 0.910 |
Why?
| | Isoenzymes | 9 | 2007 | 302 | 0.690 |
Why?
| | Hypertension, Pulmonary | 12 | 2021 | 1942 | 0.650 |
Why?
| | Lung | 11 | 2021 | 4137 | 0.610 |
Why?
| | Evans Blue | 1 | 2018 | 8 | 0.590 |
Why?
| | Capillary Permeability | 1 | 2018 | 149 | 0.550 |
Why?
| | Cell Division | 25 | 2009 | 798 | 0.530 |
Why?
| | Protein Kinase C-epsilon | 3 | 2005 | 24 | 0.530 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2019 | 260 | 0.510 |
Why?
| | Muscle Proteins | 1 | 2017 | 240 | 0.480 |
Why?
| | Blood Vessels | 3 | 2016 | 180 | 0.470 |
Why?
| | Endothelium, Vascular | 2 | 2020 | 951 | 0.400 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2013 | 29 | 0.390 |
Why?
| | Aging | 4 | 2020 | 1924 | 0.380 |
Why?
| | Mice, Knockout | 6 | 2017 | 3071 | 0.370 |
Why?
| | Animals | 44 | 2021 | 37749 | 0.370 |
Why?
| | Animals, Newborn | 10 | 2007 | 870 | 0.350 |
Why?
| | Airway Remodeling | 1 | 2010 | 70 | 0.320 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 3 | 2017 | 1048 | 0.300 |
Why?
| | Cattle | 16 | 2002 | 998 | 0.280 |
Why?
| | Fibroblasts | 7 | 2019 | 1021 | 0.250 |
Why?
| | Mice | 14 | 2018 | 18109 | 0.240 |
Why?
| | Endothelin-1 | 2 | 2017 | 177 | 0.230 |
Why?
| | Protein Kinases | 1 | 2007 | 308 | 0.230 |
Why?
| | Signal Transduction | 7 | 2020 | 5169 | 0.210 |
Why?
| | Enzyme Activation | 5 | 2017 | 811 | 0.210 |
Why?
| | Lung Neoplasms | 11 | 2012 | 2567 | 0.210 |
Why?
| | rho-Associated Kinases | 2 | 2019 | 84 | 0.200 |
Why?
| | Cells, Cultured | 12 | 2017 | 4212 | 0.190 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2002 | 54 | 0.190 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 3 | 2012 | 85 | 0.190 |
Why?
| | Lung Diseases | 2 | 2007 | 793 | 0.190 |
Why?
| | Insulin-Like Growth Factor I | 3 | 1997 | 325 | 0.190 |
Why?
| | Vascular Remodeling | 2 | 2021 | 196 | 0.190 |
Why?
| | Vasoconstriction | 1 | 2002 | 219 | 0.180 |
Why?
| | Growth Substances | 4 | 1997 | 148 | 0.180 |
Why?
| | Mice, Inbred C57BL | 5 | 2017 | 5909 | 0.170 |
Why?
| | Tetradecanoylphorbol Acetate | 5 | 1997 | 156 | 0.170 |
Why?
| | Cell Movement | 3 | 2017 | 990 | 0.170 |
Why?
| | Butyrates | 1 | 2021 | 61 | 0.170 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2020 | 163 | 0.160 |
Why?
| | Metabolic Diseases | 1 | 2021 | 114 | 0.160 |
Why?
| | Mitogens | 2 | 1997 | 59 | 0.160 |
Why?
| | Forkhead Box Protein O3 | 1 | 2020 | 17 | 0.160 |
Why?
| | Vasa Vasorum | 1 | 2020 | 25 | 0.160 |
Why?
| | Phenotype | 5 | 2017 | 3177 | 0.160 |
Why?
| | Platelet-Derived Growth Factor | 3 | 1997 | 93 | 0.160 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2021 | 226 | 0.160 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2020 | 159 | 0.160 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2019 | 88 | 0.150 |
Why?
| | Genotype | 2 | 2017 | 1866 | 0.150 |
Why?
| | Cellular Microenvironment | 1 | 2019 | 91 | 0.150 |
Why?
| | Pulmonary Alveoli | 2 | 2012 | 414 | 0.140 |
Why?
| | Metabolome | 1 | 2021 | 366 | 0.140 |
Why?
| | Thymidine | 5 | 1996 | 60 | 0.140 |
Why?
| | ets-Domain Protein Elk-1 | 1 | 2017 | 12 | 0.140 |
Why?
| | Smooth Muscle Myosins | 1 | 2017 | 6 | 0.140 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2017 | 67 | 0.130 |
Why?
| | Actins | 3 | 2017 | 424 | 0.130 |
Why?
| | Microfilament Proteins | 1 | 2017 | 134 | 0.130 |
Why?
| | Vascular Diseases | 1 | 2019 | 244 | 0.120 |
Why?
| | Substance P | 1 | 2016 | 37 | 0.120 |
Why?
| | Calcium-Binding Proteins | 1 | 2017 | 217 | 0.120 |
Why?
| | Doxycycline | 1 | 2016 | 61 | 0.120 |
Why?
| | Duodenum | 1 | 2016 | 74 | 0.120 |
Why?
| | Chronic Disease | 6 | 2009 | 1820 | 0.120 |
Why?
| | Neovascularization, Pathologic | 5 | 2020 | 296 | 0.120 |
Why?
| | Pneumonia | 1 | 2021 | 656 | 0.120 |
Why?
| | Sleep Apnea Syndromes | 2 | 2013 | 90 | 0.110 |
Why?
| | Uterus | 3 | 2006 | 222 | 0.110 |
Why?
| | Carcinogens | 2 | 2012 | 128 | 0.110 |
Why?
| | In Vitro Techniques | 5 | 2007 | 1094 | 0.110 |
Why?
| | Myocardium | 1 | 2019 | 928 | 0.110 |
Why?
| | Cell Communication | 1 | 1996 | 318 | 0.110 |
Why?
| | Sputum | 3 | 2005 | 313 | 0.110 |
Why?
| | Endothelial Cells | 3 | 2021 | 816 | 0.100 |
Why?
| | Humans | 30 | 2021 | 141754 | 0.100 |
Why?
| | Estradiol | 2 | 1997 | 528 | 0.100 |
Why?
| | Enzyme Inhibitors | 4 | 2002 | 855 | 0.100 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 1997 | 876 | 0.100 |
Why?
| | Blotting, Western | 3 | 2012 | 1234 | 0.090 |
Why?
| | Quinazolines | 2 | 2012 | 260 | 0.090 |
Why?
| | Cell Proliferation | 2 | 2017 | 2506 | 0.090 |
Why?
| | Piperidines | 2 | 2012 | 218 | 0.090 |
Why?
| | Gene Expression Regulation | 3 | 2016 | 2608 | 0.090 |
Why?
| | Bronchoscopy | 5 | 2009 | 226 | 0.090 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2005 | 274 | 0.090 |
Why?
| | Mice, Transgenic | 1 | 2016 | 2184 | 0.080 |
Why?
| | DNA Primers | 2 | 2009 | 510 | 0.080 |
Why?
| | Somatomedins | 1 | 1990 | 28 | 0.080 |
Why?
| | Arteries | 2 | 2006 | 262 | 0.080 |
Why?
| | Carcinoma in Situ | 3 | 2005 | 43 | 0.080 |
Why?
| | Precancerous Conditions | 3 | 2004 | 166 | 0.080 |
Why?
| | Maleimides | 3 | 2000 | 21 | 0.080 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 2096 | 0.080 |
Why?
| | Isotretinoin | 1 | 2009 | 24 | 0.080 |
Why?
| | Tocopherols | 1 | 2009 | 26 | 0.080 |
Why?
| | ErbB Receptors | 1 | 2012 | 610 | 0.070 |
Why?
| | Cell Hypoxia | 3 | 1999 | 231 | 0.070 |
Why?
| | Blood Pressure | 3 | 2021 | 1748 | 0.070 |
Why?
| | Biomarkers | 1 | 2020 | 4190 | 0.070 |
Why?
| | Biomarkers, Tumor | 3 | 2012 | 1258 | 0.070 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2005 | 645 | 0.070 |
Why?
| | Galectin 1 | 1 | 2006 | 2 | 0.060 |
Why?
| | Bronchi | 2 | 2000 | 267 | 0.060 |
Why?
| | Genes, ras | 2 | 1997 | 95 | 0.060 |
Why?
| | Female | 17 | 2012 | 75943 | 0.060 |
Why?
| | Hyperoxia | 1 | 2007 | 91 | 0.060 |
Why?
| | Heart Failure | 1 | 2019 | 2093 | 0.060 |
Why?
| | Videotape Recording | 1 | 2006 | 39 | 0.060 |
Why?
| | Thiazolidinediones | 1 | 2006 | 138 | 0.060 |
Why?
| | Indoles | 3 | 2000 | 478 | 0.060 |
Why?
| | Male | 10 | 2018 | 70179 | 0.060 |
Why?
| | Hypertrophy, Right Ventricular | 2 | 2021 | 147 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 3 | 2021 | 2525 | 0.060 |
Why?
| | Smoking | 4 | 2009 | 1603 | 0.060 |
Why?
| | DNA | 4 | 1997 | 1444 | 0.060 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2005 | 174 | 0.060 |
Why?
| | Blood | 2 | 1995 | 113 | 0.060 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2005 | 200 | 0.050 |
Why?
| | Endothelins | 2 | 1996 | 63 | 0.050 |
Why?
| | Rats | 4 | 2021 | 5637 | 0.050 |
Why?
| | Disease Models, Animal | 2 | 2013 | 4421 | 0.050 |
Why?
| | Calcium | 2 | 2002 | 1192 | 0.050 |
Why?
| | Drug Synergism | 3 | 1996 | 375 | 0.050 |
Why?
| | Guinea Pigs | 3 | 2006 | 171 | 0.050 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 1997 | 650 | 0.050 |
Why?
| | Hemodynamics | 1 | 2009 | 1100 | 0.050 |
Why?
| | Drug Delivery Systems | 1 | 2007 | 363 | 0.050 |
Why?
| | Shaw Potassium Channels | 1 | 2002 | 4 | 0.050 |
Why?
| | Potassium Chloride | 1 | 2002 | 42 | 0.050 |
Why?
| | Stem Cells | 1 | 2007 | 603 | 0.050 |
Why?
| | Fetus | 2 | 1997 | 802 | 0.050 |
Why?
| | Potassium Channel Blockers | 1 | 2002 | 47 | 0.050 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2005 | 467 | 0.050 |
Why?
| | Case-Control Studies | 1 | 2010 | 3597 | 0.050 |
Why?
| | Angiotensin II | 1 | 2002 | 99 | 0.050 |
Why?
| | Nitric Oxide Synthase | 1 | 2002 | 242 | 0.050 |
Why?
| | Potassium Channels | 1 | 2002 | 149 | 0.050 |
Why?
| | Tunica Media | 2 | 1998 | 36 | 0.040 |
Why?
| | Urethane | 2 | 2012 | 43 | 0.040 |
Why?
| | Protein Kinase C beta | 2 | 2000 | 20 | 0.040 |
Why?
| | Systole | 1 | 2021 | 175 | 0.040 |
Why?
| | Gene Deletion | 1 | 2002 | 389 | 0.040 |
Why?
| | Antineoplastic Agents | 2 | 2010 | 2169 | 0.040 |
Why?
| | Fluorescence | 1 | 2001 | 161 | 0.040 |
Why?
| | Tight Junctions | 1 | 2021 | 78 | 0.040 |
Why?
| | Patient Education as Topic | 1 | 2006 | 779 | 0.040 |
Why?
| | Acetylation | 1 | 2021 | 245 | 0.040 |
Why?
| | Microvessels | 1 | 2021 | 86 | 0.040 |
Why?
| | Nitric Oxide | 1 | 2005 | 900 | 0.040 |
Why?
| | Receptors, Purinergic P2Y | 1 | 2020 | 7 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 1 | 2009 | 2375 | 0.040 |
Why?
| | Macrophages | 2 | 2021 | 1562 | 0.040 |
Why?
| | Ligands | 1 | 2021 | 667 | 0.040 |
Why?
| | Cytokines | 2 | 2021 | 2100 | 0.040 |
Why?
| | Aged | 6 | 2010 | 24746 | 0.040 |
Why?
| | GTPase-Activating Proteins | 1 | 2019 | 85 | 0.040 |
Why?
| | Guanine Nucleotide Exchange Factors | 1 | 2019 | 66 | 0.040 |
Why?
| | Trans-Activators | 1 | 2001 | 394 | 0.040 |
Why?
| | Light | 1 | 2001 | 395 | 0.040 |
Why?
| | Up-Regulation | 1 | 2021 | 860 | 0.040 |
Why?
| | Immune System | 1 | 2019 | 183 | 0.030 |
Why?
| | Leukocytes | 1 | 2019 | 309 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2020 | 368 | 0.030 |
Why?
| | Culture Media, Serum-Free | 1 | 1997 | 46 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 1997 | 39 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2020 | 444 | 0.030 |
Why?
| | Aorta | 2 | 2001 | 424 | 0.030 |
Why?
| | Disease Susceptibility | 1 | 2019 | 353 | 0.030 |
Why?
| | Neoplasms | 1 | 2013 | 2747 | 0.030 |
Why?
| | Oxygen | 1 | 2002 | 992 | 0.030 |
Why?
| | Adenosine Triphosphate | 1 | 2020 | 492 | 0.030 |
Why?
| | Protein Kinase C-alpha | 1 | 1997 | 37 | 0.030 |
Why?
| | Ischemia | 1 | 2000 | 415 | 0.030 |
Why?
| | Organ Specificity | 1 | 1997 | 312 | 0.030 |
Why?
| | Pregnancy, Animal | 1 | 1997 | 52 | 0.030 |
Why?
| | Bronchial Neoplasms | 1 | 1996 | 16 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2020 | 429 | 0.030 |
Why?
| | Muscle Development | 1 | 1997 | 114 | 0.030 |
Why?
| | Sensitivity and Specificity | 2 | 2001 | 1977 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2001 | 719 | 0.030 |
Why?
| | Heart Ventricles | 1 | 2021 | 753 | 0.030 |
Why?
| | Microcirculation | 2 | 2007 | 150 | 0.030 |
Why?
| | Species Specificity | 1 | 1997 | 583 | 0.030 |
Why?
| | Rabbits | 1 | 1997 | 754 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2019 | 634 | 0.030 |
Why?
| | Blood Physiological Phenomena | 1 | 1996 | 13 | 0.030 |
Why?
| | Receptors, Platelet-Derived Growth Factor | 1 | 1996 | 14 | 0.030 |
Why?
| | Tritium | 1 | 1996 | 72 | 0.030 |
Why?
| | Point Mutation | 1 | 1997 | 237 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2010 | 2064 | 0.030 |
Why?
| | Rats, Inbred Strains | 1 | 1996 | 345 | 0.030 |
Why?
| | Neoplasms, Second Primary | 1 | 1997 | 110 | 0.030 |
Why?
| | Middle Aged | 5 | 2010 | 34647 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 1996 | 398 | 0.030 |
Why?
| | Protein Precursors | 1 | 1996 | 134 | 0.030 |
Why?
| | Myocytes, Cardiac | 1 | 2019 | 536 | 0.030 |
Why?
| | Catalysis | 1 | 1995 | 320 | 0.030 |
Why?
| | Subcellular Fractions | 1 | 1994 | 78 | 0.030 |
Why?
| | Adenosine Diphosphate | 1 | 1994 | 82 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1057 | 0.030 |
Why?
| | Exercise | 1 | 2006 | 2112 | 0.030 |
Why?
| | Models, Biological | 1 | 2021 | 1828 | 0.030 |
Why?
| | Flow Cytometry | 2 | 1996 | 1197 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 1997 | 1363 | 0.030 |
Why?
| | Poly I-C | 1 | 1994 | 64 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 1996 | 489 | 0.030 |
Why?
| | Blood Proteins | 1 | 1996 | 250 | 0.030 |
Why?
| | Quality of Life | 1 | 2006 | 3014 | 0.030 |
Why?
| | Endothelin Receptor Antagonists | 1 | 1993 | 62 | 0.030 |
Why?
| | Young Adult | 1 | 2010 | 13749 | 0.030 |
Why?
| | Hyperplasia | 2 | 2006 | 176 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 1996 | 434 | 0.020 |
Why?
| | Complement Factor B | 1 | 1994 | 110 | 0.020 |
Why?
| | Receptors, Estrogen | 1 | 1996 | 412 | 0.020 |
Why?
| | Methylcholanthrene | 1 | 2012 | 22 | 0.020 |
Why?
| | Risk Factors | 5 | 2009 | 10482 | 0.020 |
Why?
| | Butylated Hydroxytoluene | 1 | 2012 | 37 | 0.020 |
Why?
| | Serotonin | 1 | 1994 | 323 | 0.020 |
Why?
| | Extracellular Matrix | 2 | 2006 | 556 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 209 | 0.020 |
Why?
| | Peptides, Cyclic | 1 | 1993 | 266 | 0.020 |
Why?
| | Apoptosis | 1 | 2000 | 2576 | 0.020 |
Why?
| | Time Factors | 2 | 2007 | 6966 | 0.020 |
Why?
| | Phorbol 12,13-Dibutyrate | 1 | 1991 | 8 | 0.020 |
Why?
| | Cell Count | 2 | 2006 | 326 | 0.020 |
Why?
| | Aerobiosis | 1 | 1991 | 22 | 0.020 |
Why?
| | Dimethyl Sulfoxide | 1 | 1991 | 41 | 0.020 |
Why?
| | Anaerobiosis | 1 | 1991 | 65 | 0.020 |
Why?
| | Pregnancy | 3 | 2006 | 7092 | 0.020 |
Why?
| | Adolescent | 1 | 2010 | 22130 | 0.020 |
Why?
| | Blood Platelets | 1 | 1994 | 437 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2007 | 6289 | 0.020 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2012 | 213 | 0.020 |
Why?
| | Tumor Cells, Cultured | 3 | 1996 | 962 | 0.020 |
Why?
| | Chemoprevention | 1 | 2010 | 95 | 0.020 |
Why?
| | Biopsy | 2 | 2005 | 1083 | 0.020 |
Why?
| | Protein Binding | 1 | 1996 | 2242 | 0.020 |
Why?
| | DNA Replication | 1 | 1991 | 240 | 0.020 |
Why?
| | Antioxidants | 1 | 2012 | 599 | 0.020 |
Why?
| | Down-Regulation | 1 | 1990 | 641 | 0.020 |
Why?
| | RNA, Messenger | 1 | 1996 | 2828 | 0.020 |
Why?
| | Leukocyte Common Antigens | 1 | 2007 | 90 | 0.020 |
Why?
| | Kinetics | 1 | 1991 | 1655 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2010 | 420 | 0.020 |
Why?
| | Rats, Inbred WKY | 1 | 2006 | 36 | 0.020 |
Why?
| | Elastin | 1 | 2006 | 79 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2006 | 68 | 0.020 |
Why?
| | Codon | 2 | 1997 | 92 | 0.020 |
Why?
| | PPAR gamma | 1 | 2006 | 181 | 0.010 |
Why?
| | Serum | 1 | 2006 | 60 | 0.010 |
Why?
| | Vascular Resistance | 1 | 2006 | 364 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 2006 | 521 | 0.010 |
Why?
| | Aged, 80 and over | 2 | 2009 | 7923 | 0.010 |
Why?
| | Collagen | 1 | 2006 | 460 | 0.010 |
Why?
| | Protein Kinase Inhibitors | 1 | 2010 | 919 | 0.010 |
Why?
| | Sheep | 1 | 2006 | 874 | 0.010 |
Why?
| | Teaching | 1 | 2006 | 237 | 0.010 |
Why?
| | Polymerase Chain Reaction | 2 | 1997 | 1056 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2004 | 329 | 0.010 |
Why?
| | Neoplasm Invasiveness | 1 | 2005 | 510 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 2010 | 896 | 0.010 |
Why?
| | Vital Capacity | 1 | 2004 | 306 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 1474 | 0.010 |
Why?
| | Epithelial Cells | 2 | 2001 | 1114 | 0.010 |
Why?
| | Base Sequence | 1 | 2006 | 2180 | 0.010 |
Why?
| | Forced Expiratory Volume | 1 | 2004 | 484 | 0.010 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2009 | 1078 | 0.010 |
Why?
| | Activities of Daily Living | 1 | 2006 | 427 | 0.010 |
Why?
| | Gestational Age | 1 | 2006 | 959 | 0.010 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2007 | 403 | 0.010 |
Why?
| | CREB-Binding Protein | 1 | 2001 | 33 | 0.010 |
Why?
| | Metaplasia | 1 | 2001 | 58 | 0.010 |
Why?
| | Patient Compliance | 1 | 2006 | 611 | 0.010 |
Why?
| | Single-Blind Method | 1 | 2001 | 289 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 1 | 2001 | 386 | 0.010 |
Why?
| | Adaptation, Psychological | 1 | 2006 | 681 | 0.010 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2000 | 46 | 0.010 |
Why?
| | Loss of Heterozygosity | 1 | 2000 | 51 | 0.010 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2000 | 50 | 0.010 |
Why?
| | Ki-67 Antigen | 1 | 2000 | 111 | 0.010 |
Why?
| | Carcinoma | 1 | 2001 | 230 | 0.010 |
Why?
| | Airway Obstruction | 1 | 2001 | 164 | 0.010 |
Why?
| | Fibrosis | 1 | 2002 | 542 | 0.010 |
Why?
| | Risk | 1 | 2001 | 907 | 0.010 |
Why?
| | Cell Death | 1 | 2000 | 387 | 0.010 |
Why?
| | Prevalence | 1 | 2005 | 2799 | 0.010 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 1997 | 1127 | 0.010 |
Why?
| | Mitotic Index | 1 | 1997 | 24 | 0.010 |
Why?
| | Bromodeoxyuridine | 1 | 1997 | 80 | 0.010 |
Why?
| | Cytoskeletal Proteins | 1 | 1997 | 156 | 0.010 |
Why?
| | Tunica Intima | 1 | 1997 | 76 | 0.010 |
Why?
| | Mammals | 1 | 1999 | 287 | 0.010 |
Why?
| | Chromosome Banding | 1 | 1996 | 19 | 0.010 |
Why?
| | Myosins | 1 | 1997 | 137 | 0.010 |
Why?
| | Ploidies | 1 | 1996 | 19 | 0.010 |
Why?
| | Karyotyping | 1 | 1996 | 104 | 0.010 |
Why?
| | Ligases | 1 | 1996 | 32 | 0.010 |
Why?
| | Ovariectomy | 1 | 1997 | 158 | 0.010 |
Why?
| | Comorbidity | 1 | 2001 | 1664 | 0.010 |
Why?
| | Bronchoalveolar Lavage | 1 | 1996 | 92 | 0.010 |
Why?
| | Heparin | 1 | 1997 | 259 | 0.010 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2000 | 529 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2000 | 1739 | 0.010 |
Why?
| | Immunophenotyping | 1 | 1996 | 329 | 0.010 |
Why?
| | Regional Blood Flow | 1 | 1997 | 498 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2001 | 1487 | 0.010 |
Why?
| | HeLa Cells | 1 | 1996 | 640 | 0.010 |
Why?
| | Calcimycin | 1 | 1994 | 49 | 0.010 |
Why?
| | Epidermal Growth Factor | 1 | 1994 | 176 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 1994 | 270 | 0.010 |
Why?
| | Interferon-beta | 1 | 1994 | 94 | 0.010 |
Why?
| | Cell Survival | 1 | 1996 | 1134 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2006 | 5974 | 0.010 |
Why?
| | Mass Screening | 1 | 2001 | 1313 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 1997 | 1401 | 0.010 |
Why?
| | Prognosis | 1 | 2001 | 4080 | 0.010 |
Why?
| | Macrophage Activation | 1 | 1994 | 200 | 0.010 |
Why?
| | Adult | 2 | 2009 | 39391 | 0.010 |
Why?
| | Analysis of Variance | 1 | 1993 | 1321 | 0.010 |
Why?
| | Interferon-gamma | 1 | 1994 | 792 | 0.010 |
Why?
| | Mutation | 1 | 2000 | 4015 | 0.000 |
Why?
| | Peptides | 1 | 1994 | 979 | 0.000 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1994 | 1250 | 0.000 |
Why?
| | Retrospective Studies | 1 | 2005 | 16374 | 0.000 |
Why?
|
|
Dempsey's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|